Virtuix partners with Sirica for autism therapy deployment

Virtuix (VTIX) said it has sold and shipped 2 Omni One systems to Sirica Therapeutics, supporting movement-centered VR and AI-assisted autism therapy, as Sirica plans ~100 treatment centers in the US. The company reported FY2026 revenue up 18% to $4.3M (from ~$4.25M LTM) with positive gross margin, but still posted a net loss of $16.8M and remains unprofitable. VTIX is trading at $3.13, down 87% YTD, with InvestingPro indicating the stock is overvalued versus fair value—keeping investor sentiment cautious despite the healthcare expansion.

Analysis

The market is reacting less to one chip-design project than to the signal that AI buyers want to internalize more of the value stack. That matters for NVDA because the risk is not a sudden revenue hole; it is slower multiple expansion if customers increasingly view merchant GPUs as interchangeable for parts of the workload, especially inference. The second-order beneficiaries are the picks-and-shovels suppliers that sit behind any ASIC effort — advanced foundry, packaging, and HBM exposure — so the spend may shift from NVDA toward TSM/AVGO/ARM-linked ecosystems rather than disappear.

Time horizon matters. In the next 1-3 months, this is mostly a sentiment/headline trade unless we see a cluster of similar announcements from other frontier labs or hyperscalers. Over 6-18 months, repeated custom-silicon efforts would pressure NVDA’s pricing power and could compress the stock’s premium even if AI capex stays elevated. The key falsifier is simple: if NVDA keeps delivering upside with stable gross margin and no sign of mix erosion, the market is over-reading the headline.

VTIX looks like promotional optionality, not fundamental change. A couple of systems shipped does not alter a company with microcap revenue scale and ongoing losses; the real watch item is whether this becomes a reimbursed, repeatable channel or just a press-release tour. Contrarian view: the stock may be oversold on fundamentals already, but without proof of multi-site rollout or funding visibility, this is not yet investable on the long side.

Key Decisions for Investors

• Hedge NVDA longs with a 1-3 month 5% OTM put spread; use it as a sentiment hedge against a cluster of follow-on custom-chip headlines. Falsify/close the hedge if NVDA reclaims recent highs while gross margin guidance stays firm.
• Relative-value: long AVGO / short NVDA over 6-12 months if more AI labs or hyperscalers announce in-house silicon. Entry on a 3-5% NVDA bounce; thesis breaks if NVDA continues to expand margins and raise guide.
• Do not chase VTIX on this release. Treat it as a watch item only until there is evidence of repeatable deployments, payer support, or a material backlog. No-trade is the correct action absent follow-through data.
• Set an alert for additional custom-ASIC announcements from major AI customers over the next 30-60 days; a second or third confirmation would turn this from noise into a durable NVDA multiple-risk theme.